886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity | Zendy

AI Assistant Blog Pricing

886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.